JP2001508449A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508449A5
JP2001508449A5 JP1998531199A JP53119998A JP2001508449A5 JP 2001508449 A5 JP2001508449 A5 JP 2001508449A5 JP 1998531199 A JP1998531199 A JP 1998531199A JP 53119998 A JP53119998 A JP 53119998A JP 2001508449 A5 JP2001508449 A5 JP 2001508449A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998531199A
Other languages
English (en)
Japanese (ja)
Other versions
JP4551502B2 (ja
JP2001508449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/000532 external-priority patent/WO1998030545A1/en
Publication of JP2001508449A publication Critical patent/JP2001508449A/ja
Publication of JP2001508449A5 publication Critical patent/JP2001508449A5/ja
Application granted granted Critical
Publication of JP4551502B2 publication Critical patent/JP4551502B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53119998A 1997-01-06 1998-01-06 病原体不活化のための脆い化合物 Expired - Lifetime JP4551502B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77988597A 1997-01-06 1997-01-06
US08/779,885 1997-01-06
US77983097A 1997-01-07 1997-01-07
US08/779,830 1997-01-07
US4369697P 1997-04-15 1997-04-15
US60/043,696 1997-04-15
PCT/US1998/000532 WO1998030545A1 (en) 1997-01-06 1998-01-06 Frangible compounds for pathogen inactivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009286996A Division JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Publications (3)

Publication Number Publication Date
JP2001508449A JP2001508449A (ja) 2001-06-26
JP2001508449A5 true JP2001508449A5 (cg-RX-API-DMAC7.html) 2005-09-08
JP4551502B2 JP4551502B2 (ja) 2010-09-29

Family

ID=27366374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53119998A Expired - Lifetime JP4551502B2 (ja) 1997-01-06 1998-01-06 病原体不活化のための脆い化合物
JP2009286996A Expired - Lifetime JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009286996A Expired - Lifetime JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Country Status (9)

Country Link
EP (1) EP1021414B1 (cg-RX-API-DMAC7.html)
JP (2) JP4551502B2 (cg-RX-API-DMAC7.html)
CN (2) CN101676268B (cg-RX-API-DMAC7.html)
AT (1) ATE243198T1 (cg-RX-API-DMAC7.html)
AU (1) AU744089C (cg-RX-API-DMAC7.html)
CA (1) CA2276532C (cg-RX-API-DMAC7.html)
DE (1) DE69815703T2 (cg-RX-API-DMAC7.html)
ES (1) ES2196530T3 (cg-RX-API-DMAC7.html)
WO (1) WO1998030545A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676268B (zh) * 1997-01-06 2013-09-25 塞鲁斯公司 用于病原体灭活的脆性化合物
ES2224415T3 (es) * 1998-01-06 2005-03-01 Cerus Corporation Metodos para inhibir desactivadores patogenos en materiales biologicos.
WO1999063981A2 (en) * 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
JP2003534383A (ja) * 2000-05-31 2003-11-18 セラス コーポレイション 免疫原性が減少した赤血球の病原体不活性化溶液の調製
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
EP1365750A2 (en) * 2000-12-21 2003-12-03 Cerus Corporation Methods for inactivation of pathogens in biological materials
AU2004224425B2 (en) * 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
AU2005302256B2 (en) 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
CA2720824C (en) 2008-04-09 2021-09-14 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
IL256381B2 (en) 2015-06-26 2024-12-01 Cerus Corp Cryoprecipitate preparations and methods for their preparation
CN104991033A (zh) * 2015-08-05 2015-10-21 上海海虹实业(集团)巢湖今辰药业有限公司 一种采用一测多评法测定川芎挥发油成分的方法
CA3003097A1 (en) 2015-10-23 2017-04-27 Cerus Corporation Plasma compositions and methods of use thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018119462A1 (en) * 2016-12-23 2018-06-28 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
MX390725B (es) 2017-03-03 2025-03-21 Cerus Corp Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
CA3087253A1 (en) 2017-12-29 2019-07-04 Cerus Corporation Systems and methods for treating biological fluids
CN114173842A (zh) 2019-06-22 2022-03-11 塞鲁斯公司 生物流体处理系统
EP3991179A1 (en) 2019-06-28 2022-05-04 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020090A1 (en) * 1993-03-17 1994-09-15 Steritech, Inc. Decontaminating clinical samples
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
WO1996039818A1 (en) * 1995-06-07 1996-12-19 Cerus Corporation Treating red blood cell solutions with anti-viral agents
CN101676268B (zh) * 1997-01-06 2013-09-25 塞鲁斯公司 用于病原体灭活的脆性化合物

Similar Documents

Publication Publication Date Title
JP2000510751A5 (cg-RX-API-DMAC7.html)
JP2000509942A5 (cg-RX-API-DMAC7.html)
JP2000509637A5 (cg-RX-API-DMAC7.html)
JP2000509635A5 (cg-RX-API-DMAC7.html)
JP2002511952A5 (cg-RX-API-DMAC7.html)
JP2000507042A5 (cg-RX-API-DMAC7.html)
JP2001511042A5 (cg-RX-API-DMAC7.html)
JP2001524256A5 (cg-RX-API-DMAC7.html)
JP2002514283A5 (cg-RX-API-DMAC7.html)
JP2002509550A5 (cg-RX-API-DMAC7.html)
JP2000509587A5 (cg-RX-API-DMAC7.html)
JP2000507369A5 (cg-RX-API-DMAC7.html)
JP2000507433A5 (cg-RX-API-DMAC7.html)
JP2000510793A5 (cg-RX-API-DMAC7.html)
JP2000508022A5 (cg-RX-API-DMAC7.html)
JP2000508680A5 (cg-RX-API-DMAC7.html)
JP2000509755A5 (cg-RX-API-DMAC7.html)
JP2002511894A5 (cg-RX-API-DMAC7.html)
JP2000510247A5 (cg-RX-API-DMAC7.html)
JP2000510969A5 (cg-RX-API-DMAC7.html)
JP2000508836A5 (cg-RX-API-DMAC7.html)
JP2000508102A5 (cg-RX-API-DMAC7.html)
JP2001517990A5 (cg-RX-API-DMAC7.html)
JP2001511327A5 (cg-RX-API-DMAC7.html)
JP2000507434A5 (cg-RX-API-DMAC7.html)